Cardiometabolic characterization in metabolic dysfunction-associated fatty liver disease
[Background] To better understand the patient's heterogeneity in fatty liver disease (FLD), metabolic dysfunction–associated fatty liver disease (MAFLD) was proposed by international experts as a new nomenclature for nonalcoholic fatty liver disease (NAFLD). We aimed to evaluate the cardiovascu...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/304037 |
| Acceso en línea: | http://hdl.handle.net/10261/304037 https://api.elsevier.com/content/abstract/scopus_id/85141211469 |
| Access Level: | acceso abierto |
| Palabra clave: | Visceral adipose tissue Coronary artery calcium Epicardial adipose tissue Metabolic dysfunction-associated fatty liver disease Nonalcoholic fatty liver disease |
| Sumario: | [Background] To better understand the patient's heterogeneity in fatty liver disease (FLD), metabolic dysfunction–associated fatty liver disease (MAFLD) was proposed by international experts as a new nomenclature for nonalcoholic fatty liver disease (NAFLD). We aimed to evaluate the cardiovascular risk, assessed through coronary artery calcium (CAC) and epicardial adipose tissue (EAT), of patients without FLD and patients with FLD and its different subtypes. |
|---|